Memorial Sloan-Kettering Cancer Center (MSKCC) Memorial Sloan Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental Biology, Genomic Integrity, and Molecular Structure);Bridge Disciplines (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences), and Patient-Oriented Research (Clinical Research and Prevention, Control, and Population Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the ten research programs depends on services provided by 34 core facilities, 19 of which will receive funding from the Cancer Center Support Grant (CCSG). During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs;therefore, an expanded budget is requested to establish the laboratories of new investigators in several fields of inquiry and to support the core facilities which have grown to support the needs of the research enterprise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-45S2
Application #
8135911
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2012-12-31
Budget Start
2010-09-01
Budget End
2010-12-31
Support Year
45
Fiscal Year
2010
Total Cost
$250,000
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Arvold, Nils D; Armstrong, Terri S; Warren, Katherine E et al. (2018) Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol 20:897-906
De, Brian; Cahlon, Oren; Sine, Kevin et al. (2018) Early Axial Growth Outcomes of Pediatric Patients Receiving Proton Craniospinal Irradiation. J Pediatr Hematol Oncol 40:574-579
Chang, Kevin K; Yoon, Changhwan; Yi, Brendan C et al. (2018) Platelet-derived growth factor receptor-? and -? promote cancer stem cell phenotypes in sarcomas. Oncogenesis 7:47
Dupnik, K M; Bean, J M; Lee, M H et al. (2018) Blood transcriptomic markers of Mycobacterium tuberculosis load in sputum. Int J Tuberc Lung Dis 22:950-958
Roberts, Sheryl; Andreou, Chrysafis; Choi, Crystal et al. (2018) Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Chem Sci 9:5646-5657
Romanoff, Anya; Zabor, Emily C; Petruolo, Oriana et al. (2018) Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? Cancer 124:4314-4321
Schaff, Lauren R; Grommes, Christian (2018) Updates on Primary Central Nervous System Lymphoma. Curr Oncol Rep 20:11
Suryawanshi, Hemant; Morozov, Pavel; Straus, Alexander et al. (2018) A single-cell survey of the human first-trimester placenta and decidua. Sci Adv 4:eaau4788
Pandit-Taskar, Neeta (2018) Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods. Semin Hematol 55:22-32
Kamboj, Mini; Cohen, Nina; Huang, Yao-Ting et al. (2018) Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant :

Showing the most recent 10 out of 8799 publications